Motif Bio Plc (MTFB LN)

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus and multi-drug resistant streptococcus pneumoniae. Motif Bio plc was incorporated in 2014 and is based in London, the United Kingdom.